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Abstract
Background: Mucosal delivery of therapeutic protein drugs or vaccines is actively investigated, in
order to improve bioavailability and avoid side effects associated with systemic administration.
Orally administered bacteria, engineered to produce anti-inflammatory cytokines (IL-10, IL-1Ra),
have shown localised ameliorating effects in inflammatory gastro-intestinal conditions. However,
the possible systemic effects of mucosally delivered recombinant bacteria have not been
investigated.
Results: B. subtilis was engineered to produce the mature human IL-1 receptor antagonist (IL-1Ra).
When recombinant B. subtilis was instilled in the distal colon of rats or rabbits, human IL-1Ra was
found both in the intestinal lavage and in the serum of treated animals. The IL-1Ra protein in serum
was intact and biologically active. IL-1-induced fever, neutrophilia, hypoglycemia and hypoferremia
were inhibited in a dose-dependent fashion by intra-colon administration of IL-1Ra-producing B.
subtilis. In the mouse, intra-peritoneal treatment with recombinant B. subtilis could inhibit
endotoxin-induced shock and death. Instillation in the rabbit colon of another recombinant B.
subtilis strain, which releases bioactive human recombinant IL-1β upon autolysis, could induce fever
and eventually death, similarly to parenteral administration of high doses of IL-1β.
Conclusions:  A novel system of controlled release of pharmacologically active proteins is
described, which exploits bacterial autolysis in a non-permissive environment. Mucosal
administration of recombinant B. subtilis causes the release of cytoplasmic recombinant proteins,
which can then be found in serum and exert their biological activity in vivo systemically.
Background
The use of recombinant proteins as drugs has deeply mod-
ified the therapeutic approach to many severe diseases.
However, a variety of practical problems limits the use of
biotechnological protein drugs. Stability of the active pro-
teins, need for parenteral administration, and high costs
of the final purified materials are among the most signifi-
cant drawbacks. A way of circumventing these issues is
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represented by the direct administration of recombinant
bacteria, acting simultaneously as cell factory and delivery
system for pharmacologically active proteins. This
approach has been already extensively experimented for
the mucosal delivery of vaccine antigens [1,2]. In recent
years, the local delivery of therapeutic antibodies [3,4],
adjuvant cytokines [5,6], and anti-inflammatory
cytokines [7-9] has been successfully attempted with
food-grade bacteria (e.g.,  Lactococcus lactis,  Streptococcus
gordonii), although limited to the therapy of localised
pathologies (e.g., inflammatory bowel diseases, IBD, in
the gastro-intestinal tract).
Among anti-inflammatory strategies, both at systemic and
local level, the use of the IL-1 receptor antagonist (IL-1Ra)
has received vast attention. IL-1 is a family of cytokines
highly active in the modulation of immune amplification
and inflammation. The IL-1 family includes two agonist
proteins, IL-1α and IL-1β, and one antagonist protein, IL-
1Ra. IL-1β is a very potent immunostimulatory and
inflammatory cytokine, responsible for initiating and
amplifying the host response to invasion. If not properly
controlled, IL-1 can cause fever, acute inflammation, tis-
sue destruction, organ failure, and eventually shock and
death (reviewed in [10]). IL-1Ra inhibits IL-1 by acting as
a competitive receptor antagonist with no detectable ago-
nist activity, thus representing a natural powerful mecha-
nism to control IL-1-dependent responses and avoid
pathological derangement (reviewed in [11,12]). In
experimental animal models, IL-1Ra has demonstrated
excellent therapeutic effects against acute and chronic
inflammatory pathologies, being also effective at high
doses in prolonging survival in endotoxic shock [11-17].
In human trials, IL-1Ra has been administered to patients
with septic shock, rheumatoid arthritis, graft-versus-host
disease, and multiple sclerosis (reviewed in [11,12,16]).
While only a modest benefit was achieved in patients with
septic shock [11,12,16,18], IL-1Ra had a clear beneficial
effect in reducing joint destruction in rheumatoid arthritis
[11,12,19-21]. From the clinical experience with purified
recombinant IL-1Ra it became clear that most of the prob-
lems of variability of efficacy were due to difficulties in
adequate timing and dosage of the drug [12]. To over-
come these problems, gene therapy with adenoviral vec-
tors carrying the IL-1Ra gene has been attempted in
experimental animals, yielding promising results in mod-
els of type 1 diabetes and ischemic brain damage [22,23].
The clinical application of the gene therapy approach may
however meet with difficulties for safety reasons, besides
the problems of controlling drug release, concentration,
and localisation.
Based on previous experience of using recombinant bacte-
ria as in vivo cell factory, here we describe a novel system
of local delivery of IL-1Ra, able to achieve systemic effects.
The system exploits the ability of certain bacteria (such as
Bacillus subtilis) to undergo autolysis in non-permissive
conditions (as it occurs in the mammalian intestine)
thereby releasing the cytoplasmic proteins. Intra-colon
instillation of B. subtilis expressing recombinant human
mature IL-1Ra induces significant serum levels of the
recombinant protein in rats and rabbits, and prevents the
inflammatory effects of systemic IL-1. Intra-peritoneal
administration of recombinant B. subtilis in the mouse
could inhibit LPS-induced shock and death. Further
experimental evidence with a B. subtilis strain producing
human IL-1β demonstrates that this delivery system can
be generalised to other recombinant proteins.
Results
The ability of B. subtilis to generate spores by autolysis of
the cell wall, thereby releasing cytoplasmic proteins, was
exploited as system for delivery of proteins in vivo. Follow-
ing a sporulation signal (e.g., nutrient depletion) bacteria
undergo an autolytic process with release of most of their
cellular components and formation of a highly resistant
spore containing DNA and few essential proteins (Figure
1A). As already shown in a previous study [24], in vitro
sporulation of B. subtilis engineered for endocellular
expression of human IL-1Ra (strain pSM539) caused the
release of large amounts of intact and active recombinant
protein within a few hours after the sporulation signal
(Figure 1B). The in vitro release of intracellular recom-
binant IL-1Ra was equally evident in pSM539 Spo+ (nor-
mally sporulating) and Spo-  bacteria,  i.e.  genetically
modified cells which, in response to the sporulation sig-
nal, start the autolysis process but are unable to form a
complete spore thus undergoing complete cell destruction
(Figure 1C). Both Spo+ and Spo- strains of pSM539 were
used in subsequent in vivo experiments with identical
results.
The IL-1Ra recovered after B. subtilis autolysis  in vitro
retained full biological activity, with a specific activity of
1.1 × 106 inhibitory units (IU)/mg vs. 0.9 × 106 IU/mg of
reference standard IL-1Ra [24]. To assess whether the
recombinant protein could also be released in vivo by
engineered B. subtilis, the bacterial strain engineered with
IL-1Ra was administered intra-peritoneally in the mouse,
in the small and large intestine of rats, and in the rabbit
distal colon. The presence of human IL-1Ra was assessed
at different times after administration, both locally and in
the serum of treated animals, by Western blotting, ELISA,
and BIAcore analysis (Table 1). Intact human IL-1Ra was
found locally at high levels 3 hours after administration of
recombinant bacteria and persisted for several hours. In
the serum, intact human IL-1Ra could be found at meas-
urable levels when B. subtilis was administered intra-peri-
toneally (2/2 mice) or in the colon (5/9 rats, 27/31BMC Biotechnology 2004, 4:27 http://www.biomedcentral.com/1472-6750/4/27
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Release of IL-1Ra from recombinant B. subtilis Figure 1
Release of IL-1Ra from recombinant B. subtilis. A. Schematic representation of the life cycle of B. subtilis showing the mechanism 
of recombinant IL-1Ra release upon sporulation (autolysis with spore formation, as in Spo+ strain), and destructive autolysis 
(with cell lysis without spore formation, as in Spo- strain). B. Presence of recombinant IL-1Ra in sporulation supernatant of 
pSM539 Spo+ strain, assessed by ELISA (mean ± SEM). IL-1Ra amount in sporulation supernatants was also quantitatively evalu-
ated by laser scanning densitometry. The amount of IL-1Ra released in vitro by 0.5–0.7 × 109 bacteria (0.25 g wet weight) 3 h 
after the sporulation signal was 1.152 mg in 9.6 mg total released proteins (i.e., 12% of the total protein in the sporulation 
supernatant). Overlapping results were obtained with Spo- pSM539 cells (data not shown). C. SDS-PAGE analysis of wild-type 
B. subtilis (lane 1) and of recombinant B. subtilis pSM539 Spo- strain expressing IL-1Ra (lane 2). Asterisk indicates the migration 
position of human mature IL-1Ra. The protein identity was confirmed in Western blotting. Identical results were obtained with 
the Spo+ strain (data not shown).
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rabbits), but not when bacteria were administered in the
small intestine (0/5 rats).
The delivery of IL-1Ra at the intestinal mucosal level was
examined. Live cells of the IL-1Ra-producing pSM539
strain were instilled in the rat distal colon, a non-permis-
sive environment that does not allow B. subtilis vegetative
life [26]. As a control, animals received equal numbers of
the pSM214 strain, i.e. B. subtilis cells transformed with
the  β-lactamase-expressing control plasmid pSM214.
Data in Figure 2 show that the presence of intact IL-1Ra
can be measured both locally (in the intestinal washings)
and in serum for several hours after intra-colonic inocu-
lum of the IL-1Ra-producing B. subtilis strain pSM539,
whereas serum of animals receiving B. subtilis pSM214
remained negative. As a control, pSM539 bacteria deliv-
ered in the small intestine released detectable amounts of
IL-1Ra locally, but no IL-1Ra could be found at the serum
level (data not shown; Table 1). The serum pharmacoki-
netic parameters of IL-1Ra released by recombinant B. sub-
tilis, as compared to the purified protein administered
intra-colonically, show a few differences (Table 2). The
Cmax was higher and the Tmax quicker for the purified pro-
tein, as compared to IL-1Ra released from intra-coloni-
cally administered B. subtilis. On the other hand, the AUC/
dose was almost identical. Administration of control bac-
teria pSM214 intra-colonically together with the purified
protein did not significantly change the pharmacokinetics
parameters of IL-1Ra, except for a slight decrease of the
total dose absorbed, indicating that the physical presence
of bacteria has little effect on IL-1Ra absorption. It is con-
cluded that engineered B. subtilis delivered intra-coloni-
cally releases, conceivably by autolysis, the cytoplasmic
recombinant protein, which is subsequently absorbed
Table 1: Local and systemic IL-1Ra after administration of IL-1Ra-producing B. subtilis
Delivery of B. subtilis pSM539 Detection of IL-1Ra
Animal Route Time Local Serum
Mouse peritoneal cavity 0 h - -
3 h ++ +
6 h + -
24 h - -
Rat small intestine 0 h - -
3 h ++ -
4 h + (B: 149.4 µg) -
6 h +/- -
8 h +/- (B: 16.5 µg) -
24 h - n.t.
large intestine 0 h - -
2 h n.t. ++ (B: 0.6–1.3 µg/ml)
3 h +++ n.t.
4 h +++ ++ (B: 0.5–1.9 µg/ml)
6 h ++ +
8 h ++ + (B: 0.1–0.4 µg/ml)
24 h + n.t.
Rabbit large intestine 0 h - - (B/E: 0 µg/ml)
0.5 h n.t. + (B: 0.2–0.4 µg/ml)
1 h n.t. ++ (B/E: 0.2–1.2 µg/ml)
2 h n.t. ++ (B/E: 0.6–1.6 µg/ml)
3 h n.t. ++ (B: 0.6–2.0 µg/ml)
4 h ++ ++ (B/E: 0.4–2.1 µg/ml)
6 h n.t. ++ (B/E: 0.3–0.9 µg/ml)
8 h ++ ++ (E: 0.6–2.4 µg/ml)
24 h n.t. + (B: 0.3 µg/ml)
Mice, rats and rabbits were administered live cells of B. subtilis strain pSM539 (engineered to produce human mature IL-1Ra; 1 × 108-2 × 109 cells/
kg) into the peritoneal cavity, the small intestine, or the large intestine. Animals were sacrificed at different time points after bacterial inoculum, and 
samples of serum and intestinal washings were taken. The presence of human IL-1Ra was assessed in all samples by Western blotting. Semi-
quantitative analysis was performed after laser scanning densitometry in comparison to different amounts of standard human recombinant IL-1Ra, 
and scored as follows: -, no detection; +/- very faint and/or inconsistent detection; + consistently positive; ++ abundant detection; +++ very high 
levels. Western blotting analysis revealed that IL-1Ra recovered from serum and intestinal washings had the same molecular mass as the standard 
IL-1Ra. No proteolytic fragments or larger aggregates could be detected. For some samples, quantitative assessment of IL-1Ra was performed by 
ELISA (E) or by BIAcore (B) analysis. Assessed animals were 2–16/group/time. n.t., not tested.BMC Biotechnology 2004, 4:27 http://www.biomedcentral.com/1472-6750/4/27
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Presence of intact IL-1Ra in serum after intra-colonic administration of IL-1Ra-producing B. subtilis Figure 2
Presence of intact IL-1Ra in serum after intra-colonic administration of IL-1Ra-producing B. subtilis. Left: Human IL-1Ra in colon 
washings and in serum of rats receiving a single intra-colonic instillation of 3 × 108 live cells of B. subtilis pSM214 (β-lactamase 
control) or pSM539 (producing IL-1Ra). The presence of IL-1Ra was assessed by Western blotting on samples of colon wash-
ings (upper panel) and serum (lower panel) taken at different time points. Samples at time 0 were from animals receiving 
pSM539 immediately before sampling. Results at time 0 from rats treated with pSM214 and untreated rats were also negative 
(data not shown). An aliquot of standard human recombinant IL-1Ra (7–14 ng) was included as reference in each gel. Right: 
Presence of human IL-1Ra in serum of rabbits receiving an intra-colonic instillation of 2 × 109 live cells of B. subtilis pSM539 
(producing IL-1Ra; ● ) or pSM214 (β-lactamase control;❍ ). IL-1Ra concentration was assessed by ELISA. Data are the mean ± 
SEM of values from 3 rabbits/group in one representative experiment. Overlapping results were obtained with sera of rats 
after intra-colonic administration of recombinant B. subtilis, and by BIAcore analysis of human IL-1Ra presence in rat and rabbit 
serum samples (data not shown). Statistical significance: pSM539 vs. pSM214 p < 0.01 at every time.
Table 2: Pharmacokinetic analysis of IL-1Ra in rabbit serum after administration of IL-1Ra-producing B. subtilis
Intra-colon instillation IL-1Ra (mg/kg) Cmax (µg/ml) Tmax (min) AUC (0–6 h)/dose (g × 
h)/ml
IL-1Ra 1.00 0.482 60 1.34
IL-1Ra + pSM241 1.00 0.372 60 1.05
pSM539 0.44 0.136 200 1.10
Groups of four rabbits received an intra-colonic instillation of highly purified human recombinant IL-1Ra (1.0 mg/kg) alone or admixed with control 
pSM214 bacteria (4 × 108 cells/kg), or of IL-1Ra-producing pSM539 bacteria (4 × 108 cells/kg). Serum samples were taken just before treatment 
(time zero) and after 1, 2, 4, and 6 h from intra-colonic instillation. The presence of human IL-1Ra in serum samples was determined by ELISA.
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and can be detected intact at measurable levels in the
bloodstream.
To verify that IL-1Ra found in serum after B. subtilis
administration at the mucosal level is functional, its abil-
ity to inhibit IL-1 was evaluated both in vitro and in vivo.
In vitro, activity of standard IL-1β was assessed with the
classical co-stimulation assay on thymocytes of LPS-unre-
sponsive C3H/HeJ mice. Inhibition by IL-1Ra was evalu-
ated as capacity to decrease IL-1-induced thymocyte
proliferation. The presence of biologically active IL-1Ra
was measured as inhibition of IL-1β-induced thymocyte
proliferation by the IL-1Ra-containing serum of rabbits
administered pSM539 intra-colonically. The presence and
amount of IL-1Ra was measured by ELISA in the serum of
pSM539-treated rabbits and of control pSM214-treated or
untreated animals. As shown in Figure 3, IL-1Ra-contain-
ing serum from pSM539-treated rabbit (used at dilutions
containing from 0.1 to 10 ng/ml IL-1Ra) was as effective
in inhibiting IL-1β activity as the same concentrations of
standard purified recombinant IL-1Ra (Figure 3, left),
whereas the same dilutions of serum from pSM214-
treated or from untreated animals (devoid of IL-1Ra) did
not possess any IL-1-inhibiting activity (Figure 3, left and
right panels). To confirm that the IL-1β-inhibiting activity
observed in sera of pSM539 treated animals is indeed due
to IL-1Ra, data in the Figure 3 (right) show that the
inhibitory capacity of pSM539 serum is significantly
decreased or abolished by an antiserum against human IL-
1Ra. Thus, it can be concluded that the IL-1Ra present in
serum after intra-colonic administration of pSM539 is
biologically active.
The in vivo efficacy of IL-1Ra released by intra-colonic
pSM539 was evaluated in antagonising the effects of
parenterally administered IL-1 [27]. As shown in Figure 4
(upper left), the increase in body temperature induced in
rabbits by i.v. administration of 75 ng/kg human IL-1β
was significantly reduced by preventive intra-colonic
treatment with 2 × 109 cells of B. subtilis pSM539. The
reduction of IL-1β-induced fever was more pronounced
with lower doses of IL-1β (90% reduction of peak fever
induced by 50 ng/kg IL-1β), but it was still highly signifi-
cant when fever was induced by 100 ng/kg IL-1β (>60%
reduction of peak fever) (data not shown). To confirm
these data, the effect of intra-colonic treatment with IL-
1Ra-producing pSM539 was evaluated on other inflam-
mation-related parameters induced by IL-1β, i.e., granulo-
cytosis and decrease of blood glucose and iron
concentrations. As shown in Figure 4 (upper right), the
increase in circulating PMN induced in rats by IL-1β i.p.
was abrogated by previous intra-colonic administration of
IL-1Ra-producing pSM539 but not by the control strain
pSM214. Likewise, the IL-1β-induced decrease in the
blood levels of iron (Figure 4, lower left) and glucose (Fig-
ure 4, lower right) was still evident in animals adminis-
tered control pSM214 bacteria but was significantly
reduced by intra-colonic instillation of IL-1Ra-producing
pSM539 bacteria. It is inferred that human recombinant
IL-1Ra delivered in vivo by intra-colonic administration of
engineered  B. subtilis is biologically active and able to
counteract the systemic inflammatory effects of IL-1.
That IL-1Ra delivered by B. subtilis can have an anti-
inflammatory protective effect in vivo was shown in a
model of shock and death induced by bacterial endotoxin
(LPS) in the mouse (Figure 5), an acute syndrome in
which IL-1β plays a major role [14-16,25]. LPS-sensitive
C3H/HeOuJ mice receiving recombinant pSM539 bacte-
ria intra-peritoneally 24 hours before administration of a
lethal dose of bacterial LPS could survive significantly
longer than mice administered the control pSM214 bacte-
ria or PBS, in agreement with previous data on the efficacy
of IL-1Ra in inhibiting LPS-induced shock [13-15].
To validate the concept of delivery of bioactive recom-
binant proteins via the colonic mucosa by means of
recombinant B. subtilis, another B. subtilis strain was con-
structed (pSM261, engineered for production of human
mature IL-1β) and administered in vivo to rabbits. As
shown in Figure 6, the intra-colonic administration of 1 ×
109 live cells of B. subtilis pSM261 induced a significant
increase in body temperature, superimposable to that
caused by intra-colonic instillation of purified recom-
binant IL-1β. Furthermore, in agreement with the sys-
temic effects of massive doses of IL-1β administered
parenterally [25,28], intra-colonic administration of
pSM261 caused shock and death in 9/14 animals (64%).
It is concluded that the mucosal delivery of engineered B.
subtilis in the large intestine is a suitable system for attain-
ing significant blood levels of bioactive recombinant pro-
teins and systemic effectiveness.
Discussion
The use of live bacteria is very common in particular in
vaccinology, where attenuated or mutant bacteria have
been employed for decades as antigen carriers. The advan-
tage of live bacteria relies on their capacity of colonising
the host and enter the host organs/tissues with the same
modalities as their virulent counterparts, thus eliciting the
relevant immune response and immune memory, at vari-
ance with killed bacteria or purified bacterial compo-
nents. Thus, attenuated strains of Salmonella,  Listeria
monocytogenes,  Mycobacterium tuberculosis,  Vibrio cholerae
are being developed and used as vaccine carriers [29-31].
A further development in the use of live bacteria as
antigen carriers in vaccination exploits the technologies of
genetic engineering for introducing multiple antigens
from different micro-organisms into a single non-virulent
bacterial carrier (e.g., food-grade lactic acid bacteria), withBMC Biotechnology 2004, 4:27 http://www.biomedcentral.com/1472-6750/4/27
Page 7 of 16
(page number not for citation purposes)
the possibility of including T- and B-stimulating epitopes
from different antigens, and also to engineering into the
same carrier adjuvant sequences derived for instance from
an immunostimulating cytokine [30-34].
Among bacterial systems developed for antigen delivery in
vaccination, some strains of non-pathogenic, food-grade
or GRAS (generally regarded as safe) bacteria have been
examined for the topical delivery of pharmacologically
active protein drugs, after cell engineering with the DNA
coding for the protein of interest. This is the case of Lacto-
coccus lactis and of Streptococcus gordonii, which have been
engineered to produce recombinant antibodies, adjuvant
and anti-inflammatory cytokines, and used to deliver
Serum IL-1Ra from intra-colonic B. subtilis inhibits IL-1-induced thymocyte proliferation in vitro Figure 3
Serum IL-1Ra from intra-colonic B. subtilis inhibits IL-1-induced thymocyte proliferation in vitro. Co-stimulation of murine thy-
mocyte proliferation by IL-1β was assessed in cultures of C3H/HeJ thymocytes stimulated with a suboptimal concentration of 
PHA (1.5 µg/ml) in the absence (zero control; empty column) or in the presence of IL-1β (solid column). Left panel: Serum 
samples were taken from rabbits administered intra-colonically 3 h earlier with B. subtilis pSM539 (producing IL-1Ra; ● ) or 
pSM214 (β-lactamase control; ❍ ), and assayed by ELISA for the presence of IL-1Ra (1.99 µg/ml in the pSM539 serum; 0.00 µg/
ml in the pSM214 serum). Inhibition of IL-1β activity (30 pg/ml) was assessed as decrease of thymocyte proliferation in the 
presence of different dilutions of the pSM539 serum (1:200, 1:2,000, 1:20,000; corresponding to 10, 1, and 0.1 ng/ml IL-1Ra) 
and compared to the same concentrations of human recombinant IL-1Ra (■ ). Right panel: Thymocyte proliferation to IL-1β 
(300 pg/ml) was evaluated in the presence of rabbit serum taken 6 h after intra-colon administration of pSM539 (● ) or serum 
from the same rabbit taken before treatment (). Serum from pSM539-treated rabbit contained 1.35 µg IL-1Ra/ml (tested by 
ELISA). Serum was added at dilutions (1:450, 1:1,350, 1:4,050) containing 3, 1, and 0.3 ng/ml IL-1Ra, either alone (● ) or in the 
presence of a polyclonal antibody against human IL-1Ra (diluted 1:300; ). Untreated rabbit serum (negative for IL-1Ra in 
ELISA) was used as control at the same dilutions as pSM539 serum. Results are presented as mean ± SEM of triplicate cultures 
within single representative experiments. Statistical significance: p < 0.01 pSM539 serum (at 1, 3, 10 ng IL-1Ra/ml) vs. IL-1β 
alone and corresponding serum controls (pSM214, untreated, + anti-IL-1Ra).
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Inhibition of IL-1 systemic effects in vivo by intra-colonic administration of IL-1Ra-producing B. subtilis Figure 4
Inhibition of IL-1 systemic effects in vivo by intra-colonic administration of IL-1Ra-producing B. subtilis. Upper left: Increase in 
body temperature in rabbits treated with human recombinant IL-1β (75 ng/kg i.v.) 1 h after a intra-colonic instillation of 2 × 109 
live cells of B. subtilis pSM539 (producing IL-1Ra; ● ) or pSM214 (β-lactamase control; ❍ ). Data are the mean ± SEM of values 
from 3 rabbits/group. Difference was statistically significant with p < 0.02 at 40 and 60 min. Upper right: Granulocytosis 
induced by human recombinant IL-1β in rats. Animals were administered intra-colonically with 1 ml/kg saline ( ) or with the 
same volume of saline containing 1 × 109 live cells/kg of pSM214 () or pSM539 (■ ). After 2 h animals received 100 ng/kg 
human recombinant IL-1β i.p. A control group received saline i.p. ( ) instead of IL-1β. All animals were bled 2 h later, and the 
number of circulating PMN was evaluated cytofluorimetrically. PMN numbers are expressed as percent blood leukocytes and 
reported as the mean ± SEM of values in 3 rats/group. Lower left: Hypoferremia induced by human recombinant IL-1β in rab-
bits. Animals received two intra-colonic instillations of 1 ml/kg saline alone ( ) or containing 2 × 109 live cells of B. subtilis 
pSM539 (producing IL-1Ra; ■ ) or pSM214 (β-lactamase control; ), 3 h before and 10 min after administration of IL-1β (100 
ng/kg i.p.). Control rabbits administered intra-colonically with saline received an i.p. inoculum of saline instead of IL-1β () .  
Serum iron levels were measured 8 h later. Data are the mean ± SEM of values of 3–25 rabbits, tested in five separate experi-
ments and representative of results obtained at different times after IL-1β inoculum (4–24 h). Lower right: Hypoglycemia 
induced by human recombinant IL-1β in rats. Animals were administered intra-colonically with 1 ml/kg saline ( ) or with the 
same volume of saline containing 1 × 109 live cells/kg of pSM214 () or pSM539 (■ ). After 2 h animals received 100 ng/kg 
human recombinant IL-1β i.p. A control group received saline i.p. ( ) instead of IL-1β. All animals were bled 2 h later, and 
serum samples were assayed for glucose concentration. Data are reported as the mean ± SEM of values in 3 rats/group.
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these proteins locally at the mucosal surface after oral
administration [3-9]. The goal of these delivery
approaches was that of making the recombinant proteins
available for therapy of local pathologies or for local
effects: antibodies for passive immunotherapy of local
infections [3,4], cytokines as adjuvants for mucosal vac-
cines [5,6], inhibitory cytokines for anti-inflammatory
therapy of localised chronic inflammatory diseases (IBD-
like pathologies) [7-9]. Although undoubtely promising
and susceptible of vast applications, the method of
mucosal delivery of therapeutic protein through recom-
binant bacteria acting as cell factories needs further and
deeper investigation. This should include the central issue
of safety and contained/controlled release of recombinant
micro-organisms [8], the problem of assessing the
mucosal permanence of bacteria (extent and duration of
colonisation depending on the changes in the mucosal
environment in different conditons of health and nutri-
tion) and the extent of protein release, and the issue of
IL-1Ra-producing B. subtilis protects mice from endotoxic shock Figure 5
IL-1Ra-producing B. subtilis protects mice from endotoxic shock. LPS-sensitive C3H/HeOuJ mice (29–52 mice/group tested in 
four separate experiments) received 3 × 106 pSM539 bacteria (engineered with human mature IL-1Ra; ● ) i.p. 24 h before 
administration of LPS (15–20 mg/kg). Mice were observed for 96 h and deaths recorded. Control mice received either the B. 
subtilis strain pSM214 (β-lactamase control;) or PBS (×) 24 h before LPS administration. Statistical analysis of survival curves 
(χ2) indicated a significant increase in survival of mice receiving pSM539 as compared to controls receiving PBS or receiving 
pSM214. At 16 h difference was statistically significant at p < 0.05 vs. pSM214 but not significant vs. PBS (+). From 24 to 40 h, 
difference was statistically significant only vs. pSM214 at p < 0.01 (#). From 44 h on, difference was statistically significant vs. 
both controls at p < 0.01 (*). Comparison of survival percentiles showed a statistically significant difference (p < 0.01) between 
pSM539 and control groups pSM214 and PBS at 75% and 50% percentiles. Survival of control mice receiving pSM214 was never 
statistically different from that of mice receiving PBS (p > 0.2).
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pharmacodynamics of the delivered protein in particular
for its systemic effects, beyond the boundaries of the local
delivery environment.
The delivery system proposed here is not based on the per-
manence/colonisation capacity of bacteria in the host
mucosal surfaces, but it relies on the capacity of
sporulating bacteria of releasing intracellular proteins in
non-permissive environments. B. subtilis cells engineered
to produce human IL-1Ra were able to release the recom-
binant protein (intact and biologically active) following a
sporulation signal in vitro [24]. This observation could be
repeated in vivo, when recombinant B. subtilis cells were
inoculated in the intestine of rats or rabbits (a non-per-
missive environment that does not allow the vegetative
life of B. subtilis). The recombinant protein could be
detected locally shortly after administration of bacteria
and persisted at measurable levels for several hours.
Release and recovery of recombinant IL-1Ra was much
more abundant and consistent in the large intestine as
compared to the small intestine. Most interestingly, the
recombinant protein released from sporulating bacteria
delivered in the large intestine was absorbed in the blood-
stream at detectable levels, whereas no circulating IL-1Ra
could be found after bacterial delivery in the small intes-
tine. IL-1Ra present in the blood was intact, as judged by
its molecular mass in Western blotting, and retained full
IL-1-inhibiting activity, as judged by its capacity of dose-
dependent neutralisation of IL-1β in vitro. The passage of
an intact protein from the intestinal lumen to the blood-
stream is not a new concept. Indeed, transcytosis has been
extensively described in intestinal epithelial cells, and
allows transport of intact proteins and macromolecules
from the intestinal lumen to the circulation through an
Intra-colonic administration of IL-1β-producing B. subtilis provokes fever and shock in rabbits Figure 6
Intra-colonic administration of IL-1β-producing B. subtilis provokes fever and shock in rabbits. Increase in body temperature in 
rabbits receiving a single intra-colonic instillation of 1 × 109 live cells of B. subtilis pSM261 (producing IL-1β; ● ) or pSM214 (β-
lactamase control; ❍ ). As positive control, rabbits received a single intra-colonic administration of 250 µg purified human 
recombinant IL-1β (■ ). Data are the mean ± SEM of values of 5 rabbits within a single representative experiment. In the group 
treated with IL-1β-producing pSM261 bacteria, 2/5 animals died within 30 h of hypotensive shock. From 0.5 to 3 h after treat-
ment, body temperature of pSM216-treated rabbits was significantly higher than that of animals receiving control pSM214 (§p < 
0.05;,* p < 0.01).
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endocytic non-degradative pathway in physiological con-
ditions of integrity of the intestinal mucosal barrier [35-
39]. This mechanism of transcytotic transport, quantita-
tively scarce as compared to the degradative pathway of
protein absorption, may have a role in physio-pathologi-
cal passage of antigens, allergens, and toxins.
Delivery of IL-1Ra through engineered sporulating bacte-
ria apparently had some pharmacokinetics advantages as
compared to the purified protein. Whereas the absorption
into the bloodstream was quick after administration of
the purified protein (Tmax at 60 min), IL-1Ra released from
intra-colonically administered B. subtilis had a much
slower kinetics of absorption (Tmax 200 min), as expected
by the fact that the protein must be released from bacteria
before being absorbed. Furthermore, although the Cmax
was decreased for B. subtilis IL-1Ra (136 ng/ml vs. 482 ng/
ml for the purified protein; only partially attributable to
the higher dosage of the purified protein), the AUC/dose
were almost identical. Thus, IL-1Ra delivered intra-colon-
ically by B. subtilis is absorbed into the bloodstream at a
slower and more constant rate than the purified protein
delivered in the same site, which is absorbed quickly into
the bloodstream and rapidly disappears thereafter. Thus,
it appears that bacteria do not undergo sporulation all at
the same time (which would result in a rapidly appearing
and disappearing peak of protein), but release the protein
constantly from the moment of administration for about
8 h. This would allow a controlled and sustained circulat-
ing level of the protein, thus a more favourable pharma-
codynamic profile, with a single administration.
The protein selected for in vivo delivery with B. subtilis is
the IL-1 receptor antagonist IL-1Ra, a competitive non-
activating ligand of the IL-1 receptor with IL-1 inhibitory
activity [11,12]. IL-1 is a potent inflammatory cytokine
which, in pathological conditions, is responsible of chro-
nicisation of inflammation, tissue destruction, organ fail-
ure, hypotensive shock [10]. Anti-IL-1 strategies have been
attempted in acute an chronic inflammatory diseases with
the use of recombinant IL-1Ra protein [11,12]. The poor
outcome of clinical trials in septic shock has highlighted
the problems of a therapy based on the systemic
administration of a purified recombinant protein, whose
efficacy is hampered by its rapid pharmacokinetics
[11,12,18]. At present, experimentation of therapeutic IL-
1Ra is being targeted to slowly progressive chronic
diseases with defined organ/tissue targets (e.g., rheuma-
toid arthritis) [40,41]. To achieve sustained IL-1Ra levels,
gene therapy approaches have been attempted with prom-
ising results in animal models of experimental arthritis,
ischemic brain damage, autoimmune diabetes [19-23].
However, the risk remains of side effects due to the uncon-
trolled inhibition of the physiologically important IL-1
activity. Indeed, a precise balance between between IL-1β
and IL-1Ra should be maintained for achieving proper tis-
sue homeostasis, as shown for the intestinal mucosa [42].
The drug delivery strategy here described merges the well-
known approach of vaccination with live bacteria with
that of gene therapy. The delivery of pharmacologically
active proteins by live sporulating bacteria, as described
here, presents a series of advantages over other similar
approaches. At variance with conventional gene therapy,
the gene coding for the drug protein is introduced in a
bacterial carrier rather than in host cells, a situation that
would allow a complete control of its permanence in the
body. In a previous study, intragastric or vaginal adminis-
tration of Streptococcus gordonii engineered to release
human IL-1Ra resulted in a prolonged local delivery of the
protein, consequent to the capacity of S. gordonii to colo-
nise the mucosal surfaces [9]. Mucosal delivery of IL-1Ra
(by intragastric administration of engineered S. gordonii)
also had a local therapeutic effect in a model of ulcerative
colitis [9]. The delivery system with sporulating bacteria
described here differs from that with S. gordonii, as it
causes rapid local release of the recombinant protein (e.g.
in the large intestine, where IL-1Ra peaks at 4 h and
decreases towards background at 24 h), followed by
absorption into the bloodstream. In preliminary experi-
ments in the mouse, IL-1Ra-expressing bacteria were also
administered intragastrically or subcutaneously. This
achieved appearance of human IL-1Ra in the serum, and
systemic effects of inhibition of LPS-induced shock and
death (data not shown). This is a new finding, that opens
the possibility of exploiting localised bacterial administra-
tion (e.g. at mucosal sites) for systemic drug delivery. The
amount of protein released at the mucosal site directly
correlates with the number of administered bacteria, since
the internal body environment does not sustain bacterial
replication but induces sporulation. This allows an exact
control of the dose of drug delivered and, based on the
pharmacokinetics parameters, of the blood levels that can
be reached. The same result could not be easily obtained
with S. gordonii, as amount and timing of protein release
may be influenced by variation of the colonisation capac-
ity depending on variations of environmental conditions
of the host tissues.
A problem that should be faced when using recombinant
bacteria in vivo for therapy or vaccination is that of safety
and contained release of genetically modified organisms
(GMO). The use of suicidal genes or the deletion of genes
vital for survival outside the host organism have been
explored with very promising results [8,43]. The bacterial
system proposed here can be modified in the sporulation
mechanism for the control of its survival. In preliminary
experiments, the recombinant B. subtilis pSM539 strain
was engineered in order to inactivate a gene involved in
sporulation control. As a consequence, in response to inBMC Biotechnology 2004, 4:27 http://www.biomedcentral.com/1472-6750/4/27
Page 12 of 16
(page number not for citation purposes)
vitro sporulation signals (adverse environmental condi-
tions) the mutated Spo- strain could regularly initiate the
sporulation process, undergoing cell autolysis and release
of the cytoplasmic proteins (including the recombinant
IL-1Ra), but it was incapable of eventual spore formation
and further survival. Likewise, release of the recombinant
protein from Spo- in vivo was comparable to that of Spo+
bacteria, but spores could never be recovered from intesti-
nal lavage and faeces (data not shown). This suggests that
the system can be optimised to full biological
containment and environmental safety without altering
its delivery properties.
Conclusions
The novel system of protein drug delivery here proposed
links some of the advantages of gene therapy (endog-
enous production of the relevant protein, targeted deliv-
ery) to the possibility of controlled release in terms of
timing and protein amount. Exploitation of the mecha-
nism of bacterial autolysis in non-permissive environ-
ments allows release of intracellular proteins, including
the known amount of the pharmacologically active
recombinant protein drug. The release is persistent for sev-
eral hours, allowing to maintain more constant protein
levels in the bloodstream. The system is simple, cheap,
and can be developed to full environmental safety (i.e.,
avoiding the risk of release of genetically modified bacte-
ria in the environment).
The concept that pharmacologically active proteins
released at the colonic mucosal surface can be absorbed
and reach the circulation intact and retaining full activity
(validated with two proteins with opposite effects, IL-1Ra
and IL-1β) opens promising avenues to the use of local
delivery for the therapy of systemic diseases.
Methods
Bacterial strains
Engineered B. subtilis strains were constructed as previ-
ously described in detail [44,45]. Briefly, cDNA coding for
mature human IL-1Ra (encompassing the mutation
N91>R), and cDNA coding for mature human IL-1β were
cloned between EcoRI and HindIII in pSM214, a B. subtilis
plasmid which promotes the synthesis of recombinant
products intracellularly, to obtain recombinant plasmids
pSM539 (carrying the cDNA for IL-1Ra) and pSM261
(carrying the cDNA for IL-1β). Plasmids were used to
transform the B. subtilis SMS118 strain. The pSM539-har-
bouring B. subtilis strain SMS118(pSM539) could produce
1.0–2.0 mg IL-1Ra/109 cells/0.35–0.49 g (wet weight),
after conventional culture overnight in 1 liter flasks. The
SMS118(pSM261) strain in the same culture conditions
produced 0.15–0.25 mg IL-1β/109 cells/0.35–0.49 g. As
negative control, B. subtilis strain SMS118 was trans-
formed with the pSM214 plasmid, which contains the
gene of β-lactamase (conferring resistance to penicillin).
All strains were leu-, pyrDI, npr-, apr-. Sporulation-defec-
tive (Spo-) strains were constructed by mutation in the
srfA gene, as previously described [46] and were kindly
provided by Dr. G. Grandi (Chiron S.r.l., Siena, Italy).
Bacterial preparations
Bacteria were grown in LB medium containing 5 mg/l
chloramphenicol for 7 h at 37°C under shaking and har-
vested by centrifugation (3,000 × g, 20 min, 4°C). For
sporulation supernatant preparation, 0.25 g wet weight of
bacteria (corresponding to 0.5–0.7 × 109 cells) were sus-
pended in Difco sporulating medium (bacto beef extract
3 g/l, peptone 5 g/l, NaOH 0.25 mM, MgSO4 10 mM, KCl
0.1%, MnCl2 0.1 mM, Ca(NO3)2 1 mM, FeSO4 1 mM, pH
6.8) without chloramphenicol and incubated at 35°C
with shaking. Aliquots of sporulation supernatant were
harvested by centrifugation (14,000 × g, 5 min) at differ-
ent time points. Following sporulation signals, both Spo+
and Spo- bacteria initiate the autolysis process, which ends
in cell autolysis with release of cytoplasmic content. How-
ever, whereas in Spo+ bacteria there is formation of a spore
with preservation of strain survival, Spo- bacteria are una-
ble to form a spore thus undergoing complete cell destruc-
tion (Figure 1A). Upon sporulation signals, both Spo+ and
Spo- bacteria released 100% of intracellular recombinant
products in a time-dependent fashion, with maximal
relaease between 2 an 8 h (Figure 1C) [24].
SDS-PAGE analysis
Protein samples were run on 13.5% mini SDS-PAGE
according to Lämmli [47] and stained with Coomassie R-
250. The gel was subjected to laser scanning on a Molecu-
lar Dynamics Personal Densitometer, and the densitomet-
ric analysis was made using Image Quant software
(Molecular Dynamics, Sunnyvale, CA).
Animals
Experimental animals were: female C3H/HeOuJ mice of
10–12 weeks of age (20–25 g) (for all in vivo experi-
ments), female C3H/HeJ mice of 5–8 weeks of age (for
thymocyte proliferation), female Sprague-Dawley rats
(around 300 g), and female New Zealand rabbits (1.9–2.5
kg). All animals were purchased from Charles River Italia
(Calco, Italy) and were housed in standard cages at 22 ±
1°C with 12 h light-12 h dark cycle. Animals received
standard diet and tap water ad libitum.
In vivo administration of B. subtilis
Bacteria were harvested and resuspended in LB medium
or sterile PBS.
Mice received a single intra-peritoneal injection of 0.2 ml
of bacterial suspension in PBS.BMC Biotechnology 2004, 4:27 http://www.biomedcentral.com/1472-6750/4/27
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Rats were fasted overnight before the surgical procedure
and maintained under urethane anaesthesia throughout.
Bacteria (in LB medium diluted 1:1 in PBS) were instilled
in the small intestine (duodenum) with a 22 1/2 G nee-
dle, in a volume of 1–10 ml. Two surgical ligatures were
applied, one at the beginning of the duodenum immedi-
ately below the needle entry puncture (to avoid exit of
instilled bacteria), and another one near the ileocecal
valve, to limit to the small intestine the transit of bacteria.
Intra-colon instillation was performed again with a 22 1/
2 G needle in the ceacum immediately below the ileo-cae-
cal valve, in a volume of 5–10 ml. Two surgical ligature
were applied just below the needle entry point and at the
colon terminal region, to avoid loss of bacteria. Animals
were sacrificed by exanguination at different times after
treatment, to collect blood and intestinal washings.
For intra-colonic administration of bacteria in rabbits,
animals were fasted overnight prior to treatment, then
lightly restrained in conventional stocks and maintained
conscious throughout the experiment. A rounded-tip ure-
thral catheter (Rüsh, Germany) was carefully inserted 10
cm into the distal colon via the anal route and 2 ml of B.
subtilis  suspension were administered. Serum samples
were prepared from blood collected from the rabbit mar-
ginal ear vein at different times (0–8 h) after intra-colonic
administration of bacteria. In some experiments, animals
were sacrificed, to collect the large intestine content
(saline washing).
Protocols of animal experimentation were reviewed by
the institutional ethical board for adherence to ethical
guidelines for animal research conduct (Italian D. L.vo
27/01/1992 n. 116 and corresponding EU directive 86/
609; policy of refinement, reduction and replacement
towards the use of animals for scientific procedures 99/
167/EC – Council Decision of 25/1/99), and previously
authorised by the Italian Ministry of Health.
Detection of human IL-1Ra in animal samples
Western blotting: samples were subjected to reducing
15% mini SDS-PAGE and analysed by Western blotting
using a polyclonal rabbit serum anti-human IL-1Ra and a
goat anti-rabbit IgG secondary antibody conjugated with
horseradish peroxidase, as described in detail elsewhere
[48]. Serum samples were filtered on Microcon 100
(MWCO 100,000; Amicon, Beverly, MA) before analysis.
ELISA measurement: samples were subjected to quantita-
tive determination of human IL-1Ra using a specific ELISA
(Amersham, Little Chalfont, UK), following the manufac-
turer's instructions. The lower detection limit was 20 pg/
ml. Purified human recombinant IL-1Ra was used as
standard. Serum samples were filtered on Microcon 100
(Amicon) before analysis.
Biosensor measurement: detection of IL-1Ra in serum
samples and intestinal washings was confirmed with the
biosensor BIAcore™ system (Pharmacia Biosensor AB,
Uppsala, Sweden), which allows real time biospecific
interaction analysis by means of the optical phenomenon
of surface plasmon resonance, as previously described in
detail [49]. The lower detection limit for human IL-1Ra
was 2 pg/ml.
IL-1-induced thymocyte proliferation
The classical assay of co-stimulation of murine thymocyte
proliferation was used to evaluate the bioactivity of IL-1
and IL-1Ra. Briefly, thymocytes from 5–8 week-old C3H/
HeJ mice (preferentially used because of their LPS unre-
sponsiveness) were cultured at 6 × 105  cells/well of
Cluster96 plates (Costar, Cambridge, MA) in 0.2 ml of
RPMI-1640 medium (Life Technologies, Paisley, Scot-
land) supplemented with 2 mM L-glutamine, 25 mM
HEPES buffer, 50 µg/ml gentamycin sulfate, 1.25 × 10-5 M
2-ME (all from Sigma Chemical Co.), 5% fetal bovine
serum (Hyclone, Logan, UT) for 72 h in moist air with 5%
CO2 [50]. The biological activity of IL-1β was assessed as
co-stimulation of thymocyte proliferation, by adding to
the culture wells a selected amount of human recom-
binant IL-1β (30–300 pg/ml) [51] and a suboptimal con-
centration of purified PHA (1.5 µg/ml; Murex
Diagnostics, Dartford, UK). Cells were then pulsed for 18
h with 18.5 kBq/well of [3H]TdR (sp. act. 185 GBq/mmol;
Amersham) and their proliferation was measured as radi-
olabel incorporation with a β-counter.
The biological activity of IL-1Ra was evaluated as inhibi-
tion of IL-1β-dependent thymocyte proliferation. To this
end, cells were stimulated to proliferate (with IL-1β and
PHA) in the presence of increasing concentrations of
human recombinant IL-1Ra [51] or serial dilutions of
serum from rabbits receiving pSM214 or pSM539 intra-
colonically, or from untreated rabbits. The concentration
of IL-1Ra in serum of pSM539-treated rabbits was deter-
mined by ELISA and serum was added to the cultures after
appropriate dilution. Control sera from pSM214-treated
or untreated rabbits were used at the same dilutions as IL-
1Ra-containing serum. Cell proliferation was then evalu-
ated as radiolabel incorporation as described above.
To assess that the effect of IL-1Ra-containing serum was
indeed due to IL-1Ra, a polyclonal rabbit antibody against
human IL-1Ra [48] was added to the cultures at a dilution
of 1:300, i.e. the dilution previously found to inhibit 50%
of the activity of 10 ng/ml IL-1Ra in the thymocyte assay
(not shown).
IL-1-induced fever
Rabbits were lightly restrained in conventional stocks
throughout the experiment, and accustomed to the stocksBMC Biotechnology 2004, 4:27 http://www.biomedcentral.com/1472-6750/4/27
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over a period of 2 h, to minimise variations in body tem-
perature. Body temperature was measured by means of a
cutaneous thermistor probe (TM-54/S and TMN/S; LSI-
Lastem, Settala Premenugo, Italy) placed between the left
posterior paw and the abdomen and allowed to stabilise
for 2 min. B. subtilis suspensions (2 × 109 live cells/rabbit)
were instilled in the distal colon 1 h before i.v. adminis-
tration of 50–100 ng/ml highly purified LPS-free human
recombinant IL-1β in pyrogen-free saline through the
marginal ear vein. Temperature was recorded every 20
min for 3 h starting from IL-1β administration. In experi-
ments with IL-1β-producing strain pSM261, rabbits
received an intra-colonic administration of 1 × 109
pSM214 (control) or pSM261 (IL-1β) bacteria, or 250 µg
purified human IL-1β. Temperature was recorded up to 22
h after treatment.
IL-1-induced neutrophilia, hypoferremia, hypoglycemia
Live cells of B. subtilis strains pSM214 and pSM539 were
instilled in the distal colon (1 × 109 cells/kg), 2 h before
administration of IL-1β. Blood samples were drawn 2, 4,
6, 8 and 24 h after intra-peritoneal inoculum of 0.1 µg/kg
human recombinant IL-1β. The number of circulating
neutrophils was assessed by flow cytometry. The plasma
iron concentration was determined colorimetrically with
a commercially available kit (Fe; Boehringer Mannheim,
Mannheim, Germany). Hypoferremia (60–75% decrease
of plasma iron level) was evident from 4 to 24 h after IL-
1β inoculum. The blood glucose concentration was meas-
ured in serum samples by the glucose/glucose oxidase/
peroxidase method with commercially available kits (Glu-
cose GOD Perid; Boehringer Mannheim) or by biosensor
detection with devices for diagnostic monitoring (Roche
Diagnostics, Milano, Italy). Overlapping results were
obtained in rats and rabbits.
LPS-induced shock in the mouse
LPS-sensitive C3H/HeOuJ mice received an intra-perito-
neal inoculum of 0.5 ml PBS alone or containing bacterial
suspensions (control pSM214, IL-1Ra-producing
pSM539; 3 × 106 bacteria/mouse), 24 h before i.p. admin-
istration of 15–20 mg/kg of LPS (from E. coli 055:B5;
Sigma Chemical Co., St. Louis, MO). LPS inoculum was
delayed to 24 h after bacteria administration to avoid
interference of pre-inoculum. In fact, preliminary
experiments showed that intra-peritoneal inoculum of
PBS decreased significantly LPS toxicity when adminis-
tered at shorter times before LPS (data not shown). Mice
were observed for 7 days after LPS administration and
deaths recorded.
Statistical analysis
Results are presented as mean ± SEM. Statistical signifi-
cance was assesed by two-tailed Student's t test. Compari-
son of survival curves was performed by the χ2  test.
Calculation of percentiles was performed by survival anal-
ysis. All calculations were performed with the Stratgraph-
ics Plus 5 programme (Manugistics, Inc., Rockville, MD).
List of abbreviations
IL, interleukin; IL-1, interleukin-1; IL-1Ra, interleukin-1
receptor antagonist; IBD, inflammatory bowel disease;
LPS, bacterial lipopolysaccharide, AUC, area under the
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erally regarded as safe; GMO, genetically modified
organisms.
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